Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) Insider Sells $448,130.50 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Placid Jover sold 14,150 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $448,130.50. Following the transaction, the insider owned 6,774 shares of the company’s stock, valued at $214,532.58. This trade represents a 67.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock opened at $30.46 on Thursday. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $37.35. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The business has a 50 day moving average price of $33.00 and a 200-day moving average price of $26.53. The company has a market cap of $35.02 billion, a PE ratio of 25.38, a price-to-earnings-growth ratio of 10.55 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter in the previous year, the firm earned $0.71 earnings per share. Teva Pharmaceutical Industries’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently made changes to their positions in TEVA. Norges Bank bought a new position in Teva Pharmaceutical Industries during the fourth quarter valued at about $1,098,060,000. Menora Mivtachim Holdings LTD. raised its position in Teva Pharmaceutical Industries by 31.9% in the second quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock worth $645,148,000 after acquiring an additional 9,303,978 shares during the period. Soundwatch Capital LLC bought a new stake in Teva Pharmaceutical Industries in the second quarter worth about $143,533,000. Harel Insurance Investments & Financial Services Ltd. boosted its stake in Teva Pharmaceutical Industries by 19.2% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after acquiring an additional 7,255,083 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Teva Pharmaceutical Industries by 39,228.4% during the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after acquiring an additional 6,878,304 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on TEVA shares. Barclays upped their target price on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research note on Friday, January 30th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. Piper Sandler reaffirmed an “overweight” rating and issued a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, January 21st. Finally, Scotiabank lifted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $37.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.